Drug intelligence / Profile preview

Elimune

Development stage: Unknown
Lead developer: Elorac
Modality: Small Molecules
Administration: Oral

Overview

Elimune is a prescription dietary supplement developed by Elorac, Inc., specifically formulated as an oral capsule for the management of chronic inflammatory skin conditions, primarily psoriasis. It contains a proprietary blend of natural ingredients, including Vitamin D3 (cholecalciferol), folic acid, nicotinamide (niacinamide), and the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These components are intended to provide nutritional support to modulate inflammatory pathways associated with plaque psoriasis. The product was evaluated in a Phase 2 clinical trial (NCT02251678) to assess its efficacy as a standalone or adjunctive treatment for psoriasis.

Brand names: Elimune
Other names: Elimune-Elorac-oral (capsule)Elimune Capsules

Targets

VDR (Vitamin D receptor)PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on Elimune.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elimune.

Explore the full profile